Yesafili (aflibercept-jbvf) PDUFA Date (Biocon Biologics Inc)
FDA PDUFA decision date for Yesafili (aflibercept-jbvf) is January 13, 2026. Developed by Biocon Biologics Inc. Indication: Vascular Endothelial Growth Factor Inhibitor [EPC]. Current status: Approved.
Indication
Vascular Endothelial Growth Factor Inhibitor [EPC]
Regulatory details
- Company: Biocon Biologics Inc
- Application type: sBLA
- Review type: Standard
- PDUFA date: 2026-01-13
- Outcome: Approved